Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT00062296 Completed - Lymphoma Clinical Trials

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Start date: March 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining epirubicin with rituximab may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with rituximab in treating patients who have relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

NCT ID: NCT00062140 Completed - Lymphoma Clinical Trials

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Start date: April 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Adjusting the dose of drugs used in chemotherapy such as cyclophosphamide may decrease side effects while stopping cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill cancer cells. PURPOSE: Phase I trial to study the effect on the body of dose-adjusted cyclophosphamide combined with total-body irradiation and donor stem cell transplantation in treating patients who have hematologic cancer.

NCT ID: NCT00062114 Completed - Lymphoma Clinical Trials

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Start date: April 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well giving yttrium Y 90 ibritumomab tiuxetan together with rituximab works in treating patients with progressive non-Hodgkin's lymphoma.

NCT ID: NCT00061880 Completed - Lymphoma Clinical Trials

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

Start date: February 2003
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.

NCT ID: NCT00061672 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.

NCT ID: NCT00061425 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG

Start date: August 2000
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.

NCT ID: NCT00060684 Completed - Clinical trials for Lymphoma, Small Lymphocytic

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Start date: December 2001
Phase: Phase 1
Study type: Interventional

The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.

NCT ID: NCT00060645 Completed - Multiple Myeloma Clinical Trials

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Start date: May 2003
Phase: Phase 1
Study type: Interventional

Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.

NCT ID: NCT00060632 Completed - Multiple Myeloma Clinical Trials

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Start date: April 2003
Phase: Phase 1
Study type: Interventional

Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of ridaforolimus in patients with refractory or recurrent malignancies, including myeloma and lymphoma.

NCT ID: NCT00060372 Completed - Clinical trials for Stage IV Breast Cancer

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Start date: April 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.